Abstract:BackgroundPlasma cell-free DNA metagenomic next-generation sequencing (mNGS) is a novel diagnostic tool for infectious diseases [1]. Data suggests that plasma mNGS may be useful in immunocompromised adults, changing management in up to 60% of the patients [2]. A prospective study evaluating utility of plasma mNGS for pneumonia in immunocompromised adults concluded that mNGS provided an additive diagnostic value of 12.1% [3]. A similar study in adults with febrile neutropenia reported a sensitivity and specificity of 85 and 100%, respectively [4]. However, there is limited data evaluating the utility of mNGS in immunocompromised children.MethodsWe retrospectively reviewed all pediatric immunocompromised patients who had plasma mNGS testing performed from December 2018 to July 2023 at St. Jude Children's Research Hospital. Electronic medical records were reviewed to extract relevant clinical data and microbiologic data including results of mNGS, contemporaneous cultures, and related antimicrobial treatment. Descriptive statistics are presented as frequencies and medians (interquartile range, IQR). Comparisons were performed using Fisher's exact test or Wilcoxon rank-sum test, as appropriate, using R version 3.6.3.ResultsA total of 18 immunocompromised children underwent plasma mNGS testing. Acute lymphoblastic leukemia was the most common malignancy (33.3%), followed by acute myeloid leukemia (22.2%). Two patients (11.1%) had undergone hematopoietic cell transplant, both allogeneic. At the time of testing, 16 patients (88.9%) had fever and 10 (55.6%) had an absolute neutrophil count of <500/mm3. All except one were on antimicrobial therapy at the time of testing, with a median duration of 8 days (IQR=12.25). Only 9 (50%) patients had a positive mNGS result. A positive mNGS resulted in broadening or extending antibiotics course in 4 patients (22.2%); negative mNGS results did not lead to changes in management in any of the cases. There were no significant differences in age, sex, days of fever, neutropenia, gastrointestinal (GI) symptoms, and days of fever before testing between those with positive versus negative results. However, a higher frequency of GI symptoms at the time of testing among those with positive results was observed. Clinical characteristics and impact on management in patients with positive and negative results are summarized in Table 1.ConclusionPlasma mNGS had a limited impact on the management of immunocompromised children at our institution. Negative results did not lead to de-escalation of therapy, and positive results led to additional exposure to antibiotics. Further research is needed to determine the role of mNGS in this population, and the interpretation of positive testing in the setting of gastrointestinal disease.Table 1. Summary of clinical characteristics and antimicrobial treatment [Median (IQR) or N (%)] of patients with mNGS positive and negative Total (n=18) Positive result (n=9) Negative result (n=9) p-value Age 11 (2-19)10 (12)14 (10)0.79 Sex (male) 11 (61.1)6 (66.7)5 (55.6)0.36 Baseline diagnosis •ALL 6 (33.3)4 (44.4)2 (22.2) •AML 4 (22.2)1 (11.1)3 (33.3) •HCT 1 2 (11.1)2 (22.2)0 •Solid tumor 4 (22.2)2 (22.2)2 (22.2) •Other 2 2 (11.1)02 (22.2) Indication for testing •Fever 9 (50)5 (55.6)4 (44.4) •Suspected pneumonia 8 (44.4)4 (44.4)4 (44.4) •Suspected central nervous system infection 5 (27.8)2 (22.2)3 (33.3) •Suspected musculoskeletal infection 2 (11.1)1 (11.1)1 (11.1) •Other 6 (33.3)3 (33.3)3 (33.3) Days of fever 4.5 (8)6 (7)5 (7)0.96 Concurrent GI symptoms 8 (44.4)6 (66.7)2(22.2)0.15 Neutropenia <500/mm3 10 (55.6)4 (44.4)6 (66.7)0.64 Days of antimicrobial therapy 8 (12.25)7 (7)11 (13)0.38 Type of antimicrobial therapy •Antibacterial 14 (77.8)7 (77.8)7 (77.8) •Antifungal 5 (27.8)05 (55.6) •Antiviral 2 (11.1)1 (11.1)1 (11.1) Impact on management 4 (22.2)4 (44.4)0 •Narrow therapy 000 •Broaden therapy 3 (16.7)2 (22.2)0 •Extend duration of therapy 1 (0.1)1 (11.1)01. Testing was performed on day +103 and 4 years after allogeneic HCT, respectively.2. Other baseline diagnosis were Hodgkin lymphoma and severe aplastic anemia.

Emerging Role of Plasma Microbial Cell-free DNA in the Diagnosis of Pediatric Mucormycosis

Plasma Microbial Cell-Free DNA Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections

Metagenomic Next-Generation Sequencing for Diagnostically Challenging Mucormycosis in Patients with Hematological Malignancies

Cell‐free DNA next‐generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease

Application of cell-free plasma next-generation sequencing technology in the diagnosis and management of pediatric meningitis

Diagnostic Value of Microbial Cell-free DNA Sequencing for Suspected Invasive Fungal Infections: A Retrospective Multicenter Cohort Study

Clinical features of pediatric mucormycosis: role of metagenomic next generation sequencing in diagnosis

Clinical utility of plasma microbial cell-free DNA sequencing among immunocompromised patients with pneumonia

Utility of Microbial Cell Free DNA Next-Generation Sequencing for Diagnosis and Management of Infectious Diseases

Serial Quantitation of Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive Mold Infections After Hematopoietic Cell Transplant

Comprehensive evaluation of plasma microbial cell-free DNA sequencing for predicting bloodstream and local infections in clinical practice: a multicenter retrospective study

Analytical and Clinical Validation of Direct Detection of Antimicrobial Resistance Markers by Plasma Microbial Cell-free DNA Sequencing

#97: Rapid, Noninvasive Detection of Kingella kingae Pediatric Vertebral Infections Using a Microbial Cell-free DNA Sequencing Test for Pathogen Identification

Dynamics and prognostic value of plasma cell-free DNA PCR in patients with invasive aspergillosis and mucormycosis

#14 Rapid, Non-Invasive Detection of Non-H. pylori Helicobacter Infections in Immunocompromised Children Using Microbial Cell-Free DNA Next Generation Sequencing in Plasma

Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia

Plasma Cell-free DNA Metagenomic Next-Generation Sequencing in Immunocompromised Children

Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study

Clinical Impact of Plasma Metagenomic Next-Generation Sequencing on Infection Diagnosis and Antimicrobial Therapy in Immunocompromised Patients

Utility of Plasma Cell-Free DNA Next-Generation Sequencing for Diagnosis of Infectious Diseases in Patients with Hematological Disorders.

Metagenomic next-generation sequencing as a diagnostic tool in the clinical routine of an infectious diseases department: a retrospective cohort study